The Mark Foundation announced its inaugural grant to Seattle-based oncology company, Presage Biosciences. The award will support a one-year feasibility study employing CIVO™ technology, Presage’s novel drug development platform which aims to assess drugs and drug combinations directly in patient tumors.
“We are deeply honored to be the inaugural grant award for The Mark Foundation,” said Dr. Richard Klinghoffer, Chief Scientific Officer of Presage. “Discovery of effective combinations of immune oncology agents is recognized as key to improving patient outcomes. This project aims to provide a technology to test dozens of potential combinations per patient, with the intent to dramatically accelerate advancement of life saving treatments into the cancer clinic.”
Dr. Michele Cleary, CEO of The Mark Foundation, remarked, “The development of Presage’s intratumoral microdosing platform is well aligned with The Mark Foundation’s mission of funding groundbreaking cancer research that integrates the discovery of new knowledge in biology with innovative technology solutions. The proven track record of the Presage scientific team in combining a deep understanding of tumor biology with cutting-edge approaches provides us with great confidence that our support of this endeavor will ultimately result in better options for patients with cancer.”